Neuland Laboratories
NSE: NEULANDLAB · ISIN INE794A01010 · Healthcare
₹20,533.00+697.00 (+3.51%)
Monday 9 November, 12:18 IST. Delayed. Source: Yahoo Finance.
Price chart
₹20,533.00 +697.00 (+3.51%) today
The day
- Previous close
- ₹19,836.00
- Open
- ₹19,675.00
- Day high
- ₹20,986.00
- Day low
- ₹19,601.00
Listed on NSE since 13 October 2008.
Key numbers
- Market value
- ₹25,275 Cr
- P/E (trailing)
- 55.85
- EPS (trailing)
- ₹352.73
- Price to book
- 12.45
- Dividend yield
- 0.17%
- Return on equity
- 24.8%
- Debt to equity
- 0.17
- Profit margin
- 19.6%
- Volume today
- 90,643
- Average volume
- 51,335
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹1,160.90 Cr | ₹163.52 Cr |
| FY24 | ₹1,515.66 Cr | ₹300.08 Cr |
| FY25 | ₹1,434.38 Cr | ₹260.11 Cr |
| FY26 | ₹1,932.12 Cr | ₹364.00 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹450 Cr | ₹52 Cr | – |
| Q1 FY27Apr–Jun 2026 | ₹642 Cr | ₹148 Cr | +962.4% |
| Q4 FY26Jan–Mar 2026Audited | ₹776 Cr | ₹213 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹440 Cr | ₹41 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹514 Cr | ₹0 | – |
| Q1 FY26Apr–Jun 2025 | ₹293 Cr | ₹14 Cr | – |
Source: Neuland Laboratories’s results filed with NSE, consolidated (the whole group). Net profit is the share of Neuland Laboratories’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹1,278 Cr | ₹1,102 Cr |
| Investments | ₹2 Cr | ₹2 Cr |
| Inventories | ₹552 Cr | ₹510 Cr |
| Owed by customers | ₹294 Cr | ₹541 Cr |
| Cash and equivalents | ₹54 Cr | ₹77 Cr |
| Total assets | ₹3,030 Cr | ₹2,930 Cr |
| Borrowings | ₹342 Cr | ₹197 Cr |
| Total liabilities | ₹1,000 Cr | ₹1,056 Cr |
| Shareholders’ equity | ₹2,030 Cr | ₹1,874 Cr |
Source: Neuland Laboratories’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Neuland Laboratories
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Hyderabad
- Employees
- 2,183
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Neuland Laboratories in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 34 Per Share
Dividend · ex-date 24 July 2026
- Dividend - Rs 12 Per Share
Dividend · ex-date 18 July 2025
- Annual General Meeting/Dividend - Rs 14 Per Share
Dividend · ex-date 12 July 2024
- Annual General Meeting/Dividend - Rs 10 Per Share
Dividend · ex-date 11 July 2023
- Annual General Meeting/Dividend - Rs 5 Per Share
Dividend · ex-date 14 July 2022 · record date 15 July 2022
- Annual General Meeting/Dividend - Rs 3 Per Share
Dividend · ex-date 29 June 2021
- Interim Dividend - Rs 2 Per Share
Dividend · ex-date 10 November 2020 · record date 11 November 2020
- Annual General Meeting
Action · ex-date 2 July 2020
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.